Group 1: Company Overview and Activities - Guizhou Langma Information Technology Co., Ltd. participated in the 2025 Guizhou Listed Companies Investor Reception Day and 2024 Annual Performance Briefing on May 12, 2025 [2] - The event was held online via the "Panorama Roadshow" platform, with key personnel including Chairman and General Manager Mr. Wang Wei and other executives present [2] Group 2: Product Development and Revenue - The "39AI Doctor Brain" is continuously being updated and optimized, with a focus on meeting user needs and commercializing with B-end clients such as hospitals and pharmaceutical companies [2] - The "39AI Doctor" product has been launched with features like disease diagnosis and case analysis, generating revenue in some medical institutions and pharmaceutical companies, but not significantly impacting overall company performance yet [2][3] Group 3: Financial Performance and International Revenue - The company's foreign revenue for 2024 was reported at 894,500 yuan, which constitutes a small percentage of total revenue, indicating minimal impact from current tariff policies [3] - Other income in the 2024 annual report includes software sales, rental income, and property management services [3] Group 4: Share Repurchase Plans - The company currently has no plans for share repurchase; any significant matters regarding share repurchase will be announced in accordance with regulations [3]

Group 1: ESG Initiatives - The company has disclosed ESG reports for three consecutive years, promoting sustainable development concepts [2] - An ESG working group has been established to coordinate related departments and implement ESG initiatives [2] - The company has received multiple awards for its ESG efforts, including AAA rating from Guozheng ESG and recognition in various ESG rankings [3] Group 2: Financial Performance - The company reported a decline in revenue due to extended project bidding and implementation cycles, as well as increased impairment losses [3] - In Q1 2025, the company experienced a significant net profit decrease attributed to high fixed costs and extended payment cycles from clients [3] - The company signed 31 new HI-HIS system orders in 2024, representing a 41% year-on-year increase, indicating positive market expansion [12] Group 3: Product Development and Innovation - The company is developing an intelligent medical diagnosis system that integrates traditional Chinese medicine with AI technology [4] - The CareSync system, developed in collaboration with Philips, showcases differentiated advantages in medical insurance and traditional Chinese medicine modules [5] - The company has launched various AI-driven healthcare solutions, including the MedCopilot smart health assistant and the APTS patient tracking system [7] Group 4: Market Outlook and Strategy - The company is positioned as a leader in the healthcare information technology sector, with over 20,000 implemented projects and a client base exceeding 7,000 [14] - The healthcare information technology industry is expected to grow significantly, driven by policies like the "Healthy China 2030" initiative [9] - The company emphasizes continuous improvement in market value management and investor confidence [6] Group 5: Challenges and Risks - The company faces challenges with high accounts receivable due to lengthy payment processes, although the overall bad debt risk remains low [9] - The impact of external factors, such as market conditions and project delays, has led to fluctuations in quarterly performance [5] - The transition of AI and medical information integration into tangible profits requires time and strategic execution [13]

点击 上方 硬AI 关注我们 AI医疗如何落地？ 硬·AI 作者 | 申思琦 编辑 | 硬 AI 上海交通大学医学院附属仁济医院与蚂蚁集团历时八个月共建的全国首个泌尿专科智能体日前交出成绩 单：累计服务约30万人次，相当于仁济泌尿外科全年55万门诊量的56%。 该智能体覆盖98%常见泌尿系统疾病，基于仁济97.6%疾病谱的标准化病例数据集，并嵌入20余位专科医 生梳理的知识图谱，实现从预问诊、报告解读到肿瘤分期诊断和医疗挂号等服务的一站式闭环 。 临床测评显示，150名不同级别医生在千例真实诊疗中对比后发现，借助智能体辅助， 基层医生诊断正确 率提升4–8个百分点 。 薛蔚副院长直言，" 真正重要的不是喂给大模型更多数据，而是把顶尖医生的逻辑嵌进去。 " 这一点决定了开发过程必须由 仁济泌尿科医生深度参与、蚂蚁集团软件工程师、医学标注员"组队开荒" ，共同建设对医疗文献、结构化诊疗数据的可控生成算法，并引入了人类医生的思考逻辑，让这一专科智 能体达到临床可用的程度。 支撑智能体的是蚂蚁医疗大模型 。 3月中旬公布的最新MedBench榜单中，该模型以97.5分（评测榜）和98.2分（自测榜）蝉联"双料冠军"， ...

Summary of Key Points Core Viewpoint - The global healthcare investment landscape in 2025 is characterized by a "high-low" fluctuation pattern, with significant opportunities emerging in specific sectors despite an overall decline in investment amounts [1][6]. Investment Trends - In January 2025, the total financing amount reached $8 billion, but it dropped to $3.194 billion in February, reflecting a 60% month-over-month decrease [1][6]. - The overseas market contributed 85% of the total funding, with all nine financing events exceeding $100 million coming from companies in Europe and the U.S. [3][6]. - Domestic financing in China saw 49 events totaling only $473 million, indicating a preference for more mature projects with higher certainty [3][6]. Sector Performance - The biopharmaceutical sector led with $1.214 billion in financing, accounting for 38% of the total, driven by technological breakthroughs [3][13]. - AI healthcare applications demonstrated strong fundraising capabilities, with Abridge raising $250 million and Prenuvo securing $120 million for cancer screening technology [3][21][22]. - The medical device sector showed a "blooming" trend, with OrganOx raising $142 million for organ preservation technology and VitalConnect securing $100 million for wearable health monitoring devices [4][41]. Market Dynamics - A report indicated that 73% of institutional investors are optimistic about an acceleration in mergers and acquisitions in 2025, with 54% focusing on small to mid-sized biotech firms [4]. - The secondary market's valuation pressures are leading to a rationalization in the primary market, with 63% of financing events concentrated in pre-A rounds in China [4]. - Policy support in China, including the "basic medical insurance + commercial insurance" payment system, is shortening the return cycle for innovative drugs [4]. Notable Financing Events - Eikon Therapeutics completed a $350 million Series D round, focusing on cancer and neurological disease treatments [3][16]. - OrganOx raised $142 million to support its organ transplantation technology [4][41]. - Abridge's $250 million funding will enhance its clinical reasoning engine, which is already utilized by 30% of U.S. healthcare institutions [3][21].

2025年3月28日， 清华大学将与中国工程院联合主办 "2025世界数字健康论坛" ，论坛将聚焦 "数智创新·激发健康医疗新格局" 主题，探讨如何借助数字化智能化技 术释放医疗卫生潜力，培养数智健康跨界人才，培育壮大新业态新模式，加速数字健康产业化进程，提升健康治理水平，为构建健康医疗领域新质生产力体系、推 动经济社会高质量发展提供新动能。 思宇MedTech作为"2025世界数字健康论坛"宣传单位 ，诚挚邀请各行业领军企业、创新型企业及有关机构参与本次论坛，共同探讨交流健康医疗行业数字化、智能 化转型未来方向，助力健康中国建设和全球健康事业发展。对贵公司的支持表示由衷的感谢！ 后附2024年会议总结，供感兴趣的企业参考。 一、会议时间： 2025年3月28日星期五 8:30-18:00 权威机构主办： 清华大学、中国工程院；在国家级会议"中关村论坛"上举行。 重量级嘉宾： （部分去年参会嘉宾；排名不分先后）（今年更是盛况空前） 王 辰 中国工程院副院长，中国工程院院士 董家鸿（清华大学临床医学院院长，中国工程院院士） 张伯礼（中国工程院医药卫生学部主任、中国工程院院士、国医大师） 尤 政 华中科技大学校长 ...

后附2024年会议总结，供感兴趣的企业参考。 一、会议时间： 2025年3月28日星期五 8:30-18:00 权威机构主办： 清华大学、中国工程院；在国家级会议"中关村论坛"上举行。 重量级嘉宾： （部分去年参会嘉宾；排名不分先后）（今年更是盛况空前） 王 辰 中国工程院副院长，中国工程院院士 董家鸿（清华大学临床医学院院长，中国工程院院士） 张伯礼（中国工程院医药卫生学部主任、中国工程院院士、国医大师） 2025年3月28日， 清华大学将与中国工程院联合主办 "2025世界数字健康论坛" ，论坛将聚焦 "数智创新·激发健康医疗新格局" 主题，探讨如何借助数字化智能化技 术释放医疗卫生潜力，培养数智健康跨界人才，培育壮大新业态新模式，加速数字健康产业化进程，提升健康治理水平，为构建健康医疗领域新质生产力体系、推 动经济社会高质量发展提供新动能。 思宇MedTech作为"2025世界数字健康论坛"宣传单位 ，诚挚邀请各行业领军企业、创新型企业及有关机构参与本次论坛，共同探讨交流健康医疗行业数字化、智能 化转型未来方向，助力健康中国建设和全球健康事业发展。对贵公司的支持表示由衷的感谢！ 王树新 重庆大学校长，中 ...